<DOC>
	<DOCNO>NCT01791309</DOCNO>
	<brief_summary>The purpose study test new drug combination consist two drug , vemurafenib ( also know ZelborafTM ) panitumumab ( also know VectibixTM ) . This treatment test subgroup patient colorectal cancer whose tumor change BRAF gene may make likely respond new drug combination .</brief_summary>
	<brief_title>Vemurafenib Panitumumab Combination Therapy Patients With BRAF V600E Mutated Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patient must metastatic colorectal cancer V600E BRAF mutation histologically cytologicallyconfirmed MSKCC fail respond appropriate standard therapy regimens . There limit number prior treatment regimen permit . Patient must previously receive treatment antiEGFR target antibody ( cetuximab panitumumab ) . Patient must accessible disease appropriate tumor biopsy . Patient male female ≥18 year age day sign informed consent . Patient must performance status 0 1 ECOG Performance Scale . Patient must adequate organ function indicate follow laboratory value : Hematological : Absolute neutrophil count ( ANC ) ≥1,500/μL Platelets ≥100,000/μL Hemoglobin ≥8g/dL Renal : Serum creatinine calculate creatinine clearance* ≤1.5 x upper limit normal ( ULN ) OR ≥60mL/min patient creatinine level &lt; 1.5 x institutional ULN Hepatic : Serum total bilirubin ≤1.5 x ULN OR direct bilirubin ≤ ULN patient total bilirubin level &gt; 1.5 x ULN AST ( SGOT ) ALT ( SGPT ) ≤3 x ULN ≤5 x ULN patient know liver metastasis *Creatinine clearance calculate use CockcroftGault method Female patient childbearing potential surgically sterilize must negative serum urine pregnancy test βhCG within 72 hour prior receive first dose study medication . Patient , patient 's legal representative , voluntarily agree participate give write informed consent . Patient able swallow capsule surgical anatomical condition preclude patient swallow absorb oral medication ongoing basis . Any patient meeting follow criterion eligible participate study : Patient chemotherapy , radiotherapy , biological therapy within 3 week ( 6 week nitrosoureas mitomycin C ) , recover adverse event due previous agent administer 4 week prior study day 1 . If patient residual toxicity prior treatment , oxaliplatinrelated neurotoxicity bevacizumabrelated albuminuria , toxicity must ≤ grade 1 . Patient must least 4 week post major surgical procedure , surgical wound must adequately heal ( judgment treat investigator ) . Patient currently participate participate study investigational compound device within 30 day study day 1 . Patient evidence active CNS disease ( radiographically unstable , symptomatic lesion ) . Newly diagnose , untreated brain metastasis ineligible . However , prior treatment stereotactic radiosurgery ( SRS ) , whole brain radiotherapy , surgical resection allow patient remains without evidence disease progression brain ≥ 6 week corticosteroid ≥ 3 week . Patient known hypersensitivity component study drug analog . Patient , time signing informed consent , regular user ( include `` recreational use '' ) illicit drug recent history ( within last year ) drug alcohol abuse . Patient breastfeed expect conceive father child within project duration study . Patient known Human Immunodeficiency Virus ( HIV ) positive . Patient known history interstitial pneumonitis pulmonary fibrosis . Patient mean QTc ≥450msec screen EKG . Patient history current evidence condition , therapy , lab abnormality might confound result study , interfere patient 's participation full duration study , best interest patient participate , opinion treat investigator . Patient know psychiatric substance abuse disorder would , opinion treat investigator , interfere cooperation requirement trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Vemurafenib</keyword>
	<keyword>Panitumumab</keyword>
	<keyword>V600E BRAF mutation</keyword>
	<keyword>colon</keyword>
	<keyword>12-221</keyword>
</DOC>